Stevens Capital Management LP lifted its position in Johnson & Johnson (NYSE:JNJ) by 87.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 12,320 shares of the company’s stock after purchasing an additional 5,763 shares during the period. Johnson & Johnson comprises approximately 0.6% of Stevens Capital Management LP’s portfolio, making the stock its 25th biggest holding. Stevens Capital Management LP’s holdings in Johnson & Johnson were worth $2,030,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership lifted its stake in Johnson & Johnson by 42.6% in the first quarter. Arrowstreet Capital Limited Partnership now owns 9,004,994 shares of the company’s stock worth $1,479,971,000 after acquiring an additional 2,688,957 shares during the period. BlackRock Inc. lifted its stake in Johnson & Johnson by 0.9% in the second quarter. BlackRock Inc. now owns 191,385,110 shares of the company’s stock worth $31,528,781,000 after acquiring an additional 1,694,112 shares during the period. Canada Pension Plan Investment Board lifted its stake in Johnson & Johnson by 55.4% in the first quarter. Canada Pension Plan Investment Board now owns 4,730,681 shares of the company’s stock worth $777,487,000 after acquiring an additional 1,685,664 shares during the period. Mn Services Vermogensbeheer B.V. purchased a new position in Johnson & Johnson during the second quarter valued at $191,090,000. Finally, Bank of Montreal Can lifted its position in Johnson & Johnson by 22.0% during the second quarter. Bank of Montreal Can now owns 7,072,870 shares of the company’s stock valued at $1,162,495,000 after buying an additional 1,276,479 shares during the period. Hedge funds and other institutional investors own 67.29% of the company’s stock.
JNJ has been the subject of several recent research reports. Morgan Stanley lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective for the company. in a research report on Tuesday, September 7th. Credit Suisse Group set a $193.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, June 7th. Finally, SVB Leerink reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Buy” and a consensus price target of $190.38.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 20th. The company reported $2.48 EPS for the quarter, topping the consensus estimate of $2.29 by $0.19. Johnson & Johnson had a return on equity of 37.06% and a net margin of 19.92%. The company had revenue of $23.31 billion during the quarter, compared to the consensus estimate of $22.54 billion. During the same period last year, the company earned $1.67 EPS. Johnson & Johnson’s revenue for the quarter was up 27.1% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 9.65 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Tuesday, August 24th were issued a $1.06 dividend. The ex-dividend date was Monday, August 23rd. This represents a $4.24 annualized dividend and a yield of 2.59%. Johnson & Johnson’s payout ratio is 52.80%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
See Also: Why do earnings reports matter?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.